Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-sensitive Recurrent Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07564141
What this trial is testing

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Who this might be right for
Platinum-Sensitive Ovarian CancerOvarian Cancer
Genmab 688
Large-scale testing (Phase 3)Study completedNCT00434642
What this trial is testing

Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma

Who this might be right for
Ovarian Cancer
Genentech, Inc. 484
Not applicableUnknownNCT05069818
What this trial is testing

Variance of HRD From Paired Ovarian Cancer

Who this might be right for
Ovarian CancerHRDPlatinum-sensitive Ovarian Cancer
Xiaoxiang Chen 50
Testing effectiveness (Phase 2)Ended earlyNCT00582205
What this trial is testing

Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma+1 more
University of Oklahoma 21
Early research (Phase 1)Study completedNCT03056833
What this trial is testing

Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Carcinoma
Ronald Buckanovich 35
Post-approval studies (Phase 4)Ended earlyNCT02035345
What this trial is testing

Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

Who this might be right for
Recurrent Ovarian CancerPlatinum Sensitive Ovarian Cancer
Massachusetts General Hospital 15
Large-scale testing (Phase 3)Active Not RecruitingNCT00565851
What this trial is testing

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Clear Cell AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+22 more
National Cancer Institute (NCI) 1,052
Testing effectiveness (Phase 2)Study completedNCT03657966
What this trial is testing

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer Recurrent
SOTIO a.s. 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339553
What this trial is testing

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

Who this might be right for
OvariancancerPlatinum-sensitive Recurrent
Peking University Third Hospital 30
Testing effectiveness (Phase 2)UnknownNCT04661696
What this trial is testing

Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

Who this might be right for
Ovarian Cancer
Chinese Academy of Medical Sciences 75
Testing effectiveness (Phase 2)UnknownNCT05158062
What this trial is testing

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Who this might be right for
Carcinoma, Ovarian Epithelial
Kosei Hasegawa, MD, PhD 35
Not applicableUnknownNCT06037213
What this trial is testing

A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib

Who this might be right for
Ovarian Cancer
Peking Union Medical College Hospital 500
Testing effectiveness (Phase 2)Study completedNCT00090610
What this trial is testing

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Who this might be right for
Ovarian Cancer
Duke University 150
Testing effectiveness (Phase 2)UnknownNCT01600573
What this trial is testing

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Who this might be right for
Ovarian Cancer
JSehouli 68
Large-scale testing (Phase 3)Active Not RecruitingNCT02446600
What this trial is testing

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated Carcinoma+10 more
National Cancer Institute (NCI)
Very early researchStudy completedNCT02855697
What this trial is testing

Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer

Who this might be right for
Ovarian Cancer
The Christie NHS Foundation Trust 28
Post-approval studies (Phase 4)Study completedNCT04330040
What this trial is testing

Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer

Who this might be right for
Ovarian CancerBreast Cancer
AstraZeneca 202
Very early researchStudy completedNCT04457089
What this trial is testing

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer

Who this might be right for
Recurrent Ovarian CancerPlatinum-sensitive Ovarian Cancer
Marc Goodman 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT05456685
What this trial is testing

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Who this might be right for
High Grade Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
AbbVie 125
Testing effectiveness (Phase 2)WithdrawnNCT02487849
What this trial is testing

HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma

Who this might be right for
Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Krankenhaus Barmherzige Schwestern Linz
Next Page
579